Recursion Pharmaceuticals: where biology meets technology
We speak to Recursion Pharmaceuticals about its use of artificial intelligence, data science, and robotics to create medicinal drugs more efficiently than before and at a lower cost.
In this episode, Recursion’s co-founder and CEO Chris Gibson tells Scottish Mortgage’s manager Tom Slater how the firm uses cutting-edge technologies to create novel insights about biology and chemistry that can lead to potential treatments. They discuss why Recursion’s methods mean it can target rare diseases, which might not make financial sense for more traditional drug companies to explore. In addition, they discuss the importance of company culture and taking time to onboard new recruits.
Recursion Pharmaceuticals was founded 10 years ago. It performs millions of experiments every week using high-precision robotics. Researchers then analyse the results using machine learning techniques to home in on promising drug candidates.
The company already has five drugs in clinical trials. One of these is a potential treatment for cerebral cavernous malformations, which are abnormally shaped brain or spinal cord blood vessels. These can cause seizures and problems with balance and walking. As its technology improves over time, Recursion hopes to tackle a broader range of diseases, potentially improving millions of people’s lives.
Check the podcast description to ensure this content is suitable for you. Your capital is at risk.
Recursion provides business updates and reports fourth quarter and fiscal year 2022 financial results
- Presenter: Claire Shaw
- Audio production agency: Listen
- Producer: Phil Sansom
- Executive producer: Suzy Grant
- Production manager: Niamh Kidd
- Editorial lead: Malcolm Borthwick